Twice each month the CEA Registry Blog lists recently published cost utility studies and associated papers. 35 papers were listed this time. Here's a few in our areas of research interest:
Latimer NR, Bhanu AC, Whitehurst DG. Inconsistencies in NICE guidance for acupuncture: reanalysis and discussion. Acupunct Med. 2012 Jul 3. [Epub ahead of print] PubMed PMID: 22759903.
Nguyen CM, Bounthavong M, Mendes MA, et al Cost Utility of Tumour Necrosis Factor-α Inhibitors for Rheumatoid Arthritis: An Application of Bayesian Methods for Evidence Synthesis in a Markov Model. Pharmacoeconomics. 2012 Jul 1;30(7):575-93. PubMed PMID: 22640174.
Palmer AJ, Tucker DM. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis. Prim Care Diabetes. 2012 Jul;6(2):109-21. Epub 2011 Dec 6. PubMed PMID: 22153888.
Granström O, Bergenheim K, McEwan Pet al. Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden. Prim Care Diabetes. 2012 Jul;6(2):127-36. Epub 2011 Oct 15. PubMed PMID: 22001114.
